Interpace Diagnostics

Resolving Diagnostic Uncertainty

Interpace Diagnostics provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services to physicians for numerous types of cancer, including pancreatic cancer. 

Two test reporting options are offered to aid gastroenterologists in pancreatic cancer risk stratification of indeterminate pancreatic cysts, solid tumors, and biliary strictures; PancraGEN®, a fully integrated reporting of first-line tests and procedures with molecular test results, and PanDNA®, a molecular-only reporting option for physician integration and interpretation of all test results.

With well over 56,000 tests performed, Interpace Diagnostics is a leading provider of molecular testing of indeterminate pancreatic cysts, solid tumors, and biliary strictures.

Interpace Diagnostics

interpace.com

Esther Soskel

esoskel@interpace.com

(516) 395-4328

Connect With Us on Social Media